MyFinsight
Home
Blog
About
Total revenues
$360,519K
(-73.39%↓ Y/Y)
Proceeds from issuance of
2031 convertible...
$550,000K
Net income (loss)
attributable to common...
$83,496K
(-89.59%↓ Y/Y)
Non-cash interest
expense on liability...
$65,309K
(-34.25%↓ Y/Y)
Proceeds from exercise of
options
$13,234K
(-21.62%↓ Y/Y)
Proceeds from employee
stock purchase plan
$3,163K
(11.89%↑ Y/Y)
Canceled cashflow
$277,023K
Accounts payable and
accrued expenses
$37,500K
(446.33%↑ Y/Y)
Share-based compensation
expense
$23,291K
(-36.37%↓ Y/Y)
Depreciation and
amortization
$15,874K
(7.23%↑ Y/Y)
Prepaid expenses and
other current assets
-$8,364K
(-168.57%↓ Y/Y)
Inducement expense related
to repurchase of...
$3,386K
Non-cash operating lease
expense
$1,792K
(-50.69%↓ Y/Y)
Unrealized foreign
currency transaction...
-$1,345K
(72.77%↑ Y/Y)
Deposits and other assets
-$1,009K
(-222.01%↓ Y/Y)
Deferred revenue
$718K
(-81.33%↓ Y/Y)
Amortization of debt issuance
costs
$384K
(-36.11%↓ Y/Y)
Net cash provided by
financing activities
$211,878K
(1484.61%↑ Y/Y)
Net cash provided by
operating activities
$129,113K
(-84.09%↓ Y/Y)
Canceled cashflow
$354,519K
Canceled cashflow
$113,365K
Total other segment
items
$124,888K
(-43.67%↓ Y/Y)
Employee costs
$68,348K
(-48.72%↓ Y/Y)
Program spend
$42,581K
(-56.49%↓ Y/Y)
Administrative costs
$16,548K
(-54.43%↓ Y/Y)
Cost of product,
collaboration and license...
$10,932K
(-30.81%↓ Y/Y)
Occupancy costs
$7,494K
(-45.79%↓ Y/Y)
Manufacturing costs
$6,232K
(-81.92%↓ Y/Y)
Net increase in cash
and cash...
$215,897K
(-9.19%↓ Y/Y)
Canceled cashflow
$125,094K
Repurchase of the 2026
convertible notes
$327,890K
Debt issuance costs
related to 2031...
$13,750K
Conversion of the 2026
convertible notes
$12,879K
Non-cash royalty revenue
related to sale of future...
$71,105K
(-16.44%↓ Y/Y)
Trade and royalty
receivables, net
$19,728K
(-23.80%↓ Y/Y)
Inventory, net
$15,860K
(84.61%↑ Y/Y)
Amortization of discounts on
investments, net
$4,156K
(-39.50%↓ Y/Y)
Other liabilities
-$1,816K
(89.52%↑ Y/Y)
Unrealized gain on
marketable securities -...
$700K
(-54.49%↓ Y/Y)
Sale of marketable
securities- available for...
$332,966K
(34.72%↑ Y/Y)
Sale of marketable
securities- equity...
$27,614K
(61.21%↑ Y/Y)
Net cash used in
investing activities
-$122,556K
(79.79%↑ Y/Y)
Effect of exchange rate
changes on cash
-$2,538K
(-113.37%↓ Y/Y)
Canceled cashflow
$360,580K
Purchases of marketable
securities- available for...
$466,973K
(-44.88%↓ Y/Y)
Purchases of marketable
securities- equity...
$9,019K
(-47.04%↓ Y/Y)
Acquisition of product
rights and licenses
$4,952K
(42.09%↑ Y/Y)
Purchases of fixed assets
$2,192K
(-27.92%↓ Y/Y)
Back
Back
Cash Flow
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)
source: myfinsight.com